These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9520982)

  • 1. Liver-specific MR imaging contrast agents.
    Hahn PF; Saini S
    Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of liver contrast agents: impact for clinical use.
    Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
    Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
    Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-enhanced MR imaging of the liver.
    Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
    J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
    Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
    AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
    Tanimoto A; Kuribayashi S
    Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Organ specific MRI contrast media in general practice].
    Schima W
    Wien Med Wochenschr Suppl; 2002; (113):8-11. PubMed ID: 12621828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging liver metastases: review and update.
    Kanematsu M; Kondo H; Goshima S; Kato H; Tsuge U; Hirose Y; Kim MJ; Moriyama N
    Eur J Radiol; 2006 May; 58(2):217-28. PubMed ID: 16406434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
    Petersein J; Saini S; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of fatty liver with MR imaging.
    Kreft BP; Tanimoto A; Baba Y; Zhao L; Chen J; Middleton MS; Compton CC; Finn JP; Stark DD
    J Magn Reson Imaging; 1992; 2(4):463-71. PubMed ID: 1633400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver-specific contrast agents for MRI.
    Stark DD; Elizondo G; Fretz CJ
    Invest Radiol; 1990 Sep; 25 Suppl 1():S58. PubMed ID: 2126535
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
    J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current status of the clinical development of MR contrast media].
    Laniado M; Kopp AF
    Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging.
    Kim SK; Kim SH; Lee WJ; Kim H; Seo JW; Choi D; Lim HK; Lee SJ; Lim JH
    AJR Am J Roentgenol; 2002 Sep; 179(3):741-50. PubMed ID: 12185056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs.
    Khangure MS; Hua J
    Acad Radiol; 1996 Aug; 3 Suppl 2():S458-60. PubMed ID: 8796629
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of approved MR contrast media for intravenous injection.
    Runge VM
    J Magn Reson Imaging; 2000 Aug; 12(2):205-13. PubMed ID: 10931582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real enhancement or merely increased contrast?
    Chen JH
    AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.